MRD testing will be a part of future AML clinical trials
One big development in clinical trial design in acute myeloid leukemia (AML) is the inclusion of measurable residual disease (MRD) testing. In this interview, Christopher Hourigan, MD, DPhil, of the N...
Author: VJHemOnc
Added: 07/04/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts